BRCA2 and posterior cortical atrophy: For example, a major advancement in PCa treatment in the last few years was the finding that a significant number of PCa patients harbor somatic or germline mutations in homologous recombination deficiency (HRD) genes such as BRCA1 or BRCA2, and targeting these alterations via PARP-inhibitors has been successfully tested in clinical trials, leading to FDA and EMA approval for PARP-inhibitors in mCRPC patients [4,5,6].